| |
|
|
Daewoong Pharmaceutical (069620) |
|
|
STOCK |
|
|
| Address |
223-23,SANGDAEWON 1-DONG, JUNGWON-GU, SEONGNAM-SI |
| Home Page |
www.daewoong.co.kr
|
| Established |
2002.10. 1 |
Tel |
031-741-7700 |
| Listed |
2002.11. 1 |
IR |
02-550-8202 |
| Common shares O/S |
9,878,538 |
President |
Yun,Jae Seung/Lee,Jong Uk |
| Preferred shares O/S |
|
No.of Employees |
241(2006.12) |
| The company has recorded a relatively favorable growth trend by focusing on sales of an original medical supplies, Lincese-in'. The sales sturucture has been moved to the division creating a big demand such as glycosuria,hypertension and imbecity remedy etc. The profitability will be improved because the change of sales structure and strong Korean won will lessen the burden of import raw materials. |
| It is worried that the sales increase trend is going to be slowdown due to government policy to cut down medicine price, system of positive list and FTA between Korea and US. Seles growth trend will continue based on the strong sales force and some changes of products' mixture is expected mainly in a higer value-added products. The profitability is expected to be slow down because the sales right for 'Nicostop' was completed and 'Gliati', 'Gasmotin' was changed to generic product, what's more, sales cost has increased for generic products. |
|
  |
(date: 2006.12, unit : %) |
| Name |
Daewoong |
Dae Woong Foundation |
Yoon Yeonghwan |
| Portion |
40.0 |
5.0 |
3.4 |
|
 |
(unit : %) |
| Sales |
IT Solution |
12.2 |
Cost |
Raw Materials |
|
| Gas Moten |
9.7 |
Labors |
|
| Others |
63.7 |
Overhead |
|
|
 |
(Unit : 100Mn.Won,Won) |
| Year |
02.11 |
- |
- |
- |
- |
| Type |
LI |
- |
- |
- |
- |
| Amount |
246.96 |
- |
- |
- |
- |
|
|
|
|
